Antibodies News and Research

RSS

Researchers create first usable computational model of entire SARS-COV-2 virus

Researchers at the University of Chicago have created the first usable computational model of the entire virus responsible for COVID-19-;and they are making this model widely available to help advance research during the pandemic.

8 Jan 2021

New approach to tame botulinum toxin for drug delivery

While rare, botulism can cause paralysis and is potentially fatal. It is caused by nerve-damaging toxins produced by Clostridium botulinum -- the most potent toxins known.

8 Jan 2021

Study reveals six-month consequences of COVID-19 in patients discharged from hospital

More than three quarters of COVID-19 patients have at least one ongoing symptom six months after initially becoming unwell, according to research published in The Lancet.

8 Jan 2021

Scientists gain new insight into how the immune system can be better used to destroy cancer cells

Scientists at the University of Southampton's Centre for Cancer Immunology have gained new insight into how the immune system can be better used to find and kill cancer cells.

8 Jan 2021

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

Researchers at Carnegie Mellon University report findings on an advanced nanomaterial-based biosensing platform that detects, within seconds, antibodies specific to SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

8 Jan 2021

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.

8 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Potential treatment approach to new COVID-19 variant

Researchers in the United States have demonstrated a potential new approach to treating infection with the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

7 Jan 2021

Researchers provide comprehensive molecular characterization of head and neck cancers

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

7 Jan 2021

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

Researchers receive $2.95 million grant to create improved diagnostics for worm infections

Global campaigns to eliminate two tropical parasitic worm infections have been hindered by a lack of good diagnostic tools.

7 Jan 2021

New approach produces strong antidotal efficacy in treating lethal botulism in animals

Related to new research published in the January issue of Science Translational Medicine, Patrick McNutt, PhD, of the Wake Forest Institute for Regenerative Medicine, was part of the research team that demonstrated a new "Trojan horse" approach that produces strong antidotal efficacy in treating lethal botulism in mice, guinea pigs and rhesus macaque monkeys.

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Antibodies News and Research

Researchers create first usable computational model of entire SARS-COV-2 virus

New approach to tame botulinum toxin for drug delivery

Study reveals six-month consequences of COVID-19 in patients discharged from hospital

Scientists gain new insight into how the immune system can be better used to destroy cancer cells

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

How do SARS-CoV-2 antibodies change over time in recovered patients?

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Potential role of chitinase 3-like-1 in severity of COVID-19

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

Potential treatment approach to new COVID-19 variant

Researchers provide comprehensive molecular characterization of head and neck cancers

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

CytoDel successfully delivers neuronal antibody in animal models of botulism

Researchers receive $2.95 million grant to create improved diagnostics for worm infections

New approach produces strong antidotal efficacy in treating lethal botulism in animals

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Adaptive immune system against COVID-19 can last for at least eight months

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News